Sylentis

Sylentis is a biotechnology company established in 2006 and fully owned by Pharma Mar SA (PHM:SM). Its mission is to build a solid and sustainable business and become a leader in novel drugs based on RNA interference or RNAi. RNAi is a promising approach to silence targets associated with numerous diseases and represents a new mechanism of drug action.The Sylentis pipeline focuses on indications with high market potential, including ocular diseases, inflammatory conditions, and central nervous system disorders.